公开(公告)号：US20200317780A1

公开(公告)日：2020-10-08

申请号：US16826102

申请日：2020-03-20

Applicant: Allogene Therapeutics, Inc.

Inventor： Yajin NI ,  Hongxiu NING ,  Janet M. LEE ,  Mark W. LEONARD

IPC: C07K16/28 ,  C12N5/078 ,  C12N15/113

Abstract: Provided herein are improved methods for robust TCR+ cell depletion and production of populations of TCR− cells, which can be beneficial to minimize the GvHD risk in patients receiving allogeneic CAR T cell therapy. Provided herein are methods that increase the efficiency of depleting TCR+ cells from a population of cells in order to significantly reduce any residual levels of TCR+ cells present in cell populations in which expression of endogenous TCR has been reduced or eliminated. Associated kits and cell populations are also provided.